In summary, while there is a concern over the toxicity when IFN-α/β/γ is combined with RT in treating patients with cancer, inhibition of JAKs and STATs appears to be an attractive strategy to boost therapeutic efficacy of RT, considering their prominent roles in mediating radioresistance in various types of cancer. The gene discussed is IFNA1; the disease is cancer.